Unlock instant, AI-driven research and patent intelligence for your innovation.

Compounds for regulating nmda receptor activity, pharmaceutical compositions and uses thereof

A compound and composition technology, applied in the field of compounds that regulate NMDA receptor activity, can solve the problems of addiction-induced dissociation, Rapastinel cannot be taken orally, and limited clinical application

Active Publication Date: 2021-09-10
BEIJING GREATWAY PHARMA TECH CO LTD
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, Esketamine has risks such as addiction, inducing dissociation and mania; Rapastinel cannot be taken orally and must be administered intravenously in clinical applications
This severely limits the clinical application of the above compounds

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compounds for regulating nmda receptor activity, pharmaceutical compositions and uses thereof
  • Compounds for regulating nmda receptor activity, pharmaceutical compositions and uses thereof
  • Compounds for regulating nmda receptor activity, pharmaceutical compositions and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example 1

[0104] Preparation Example 1: Synthesis of L-thiazolidinic acid

[0105]

[0106] Dissolve 12.1g (0.1mol) of L-cysteine ​​in 60ml of hot water, slowly pour into 10mL of 36% formaldehyde aqueous solution, shake well and let it stand overnight, filter the precipitated crystals the next day, and then wash with ethanol and water Recrystallization gave 12.8 g of needle-like white crystals, with a yield of 96.2%.

preparation example 2

[0107] Preparation Example 2: Synthesis of L-thiazolidinic acid methyl ester hydrochloride

[0108]

[0109] Dissolve 13.3 g (0.1 mol) of L-thiazolidinic acid in 100 ml of anhydrous methanol, pass hydrogen chloride gas until the raw materials are completely dissolved, continue to ventilate for more than 2 hours, and stir overnight after ventilating. The next day, the solvent was evaporated to dryness under reduced pressure, and the residue was dissolved in methanol and evaporated to dryness again. This was repeated twice to take away hydrogen chloride gas. The solvent was evaporated to dryness to obtain the crude product, which was recrystallized from methanol-ether with a yield of 91%.

preparation example 3

[0110] Preparation Example 3: Synthesis of N-tert-butoxycarbonyl-L-thiazolidinic acid

[0111]

[0112] Under ice bath, dissolve 0.10mol of L-thiazolidinic acid in 50mL of 2N aqueous sodium hydroxide solution (0.10mol), and mix 24.4g (0.11mol) of tert-butoxycarbonyl anhydride and 50mL of acetone with stirring Slowly added dropwise, and continued to stir for 2h. Add 200 mL of water to dilute the reaction solution, and extract 3 times with ethyl acetate, each time with 80 mL of ethyl acetate; discard the organic phase. The aqueous phase was adjusted to pH 2 with 1 mol / L hydrochloric acid in an ice bath, and extracted three times with ethyl acetate, each time using 80 mL of ethyl acetate; the organic phases were combined, dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure, and White crystals were obtained by recrystallization from petroleum ether and ethyl acetate with a yield of 88%.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of medicine and chemical industry, and relates to a compound for regulating NMDA receptor activity, a pharmaceutical composition and application thereof. Specifically, the present invention relates to the compound represented by formula I, its pharmaceutically acceptable salt or ester, its stereoisomer or its solvate. The present invention also relates to pharmaceutical compositions and kits containing the compound of formula I, and the compound of formula I is used in the preparation of treatment and / or prevention of depression, anxiety, stroke, Huntington's disease, Alzheimer's disease, neuralgia or Use in medicine for schizophrenia. NH 2 ‑P1‑P2‑P3‑P4‑COR Type I.

Description

technical field [0001] The invention belongs to the field of medicine and chemical industry, and relates to a compound for regulating NMDA receptor activity, a pharmaceutical composition and application thereof. Specifically, the present invention relates to compounds with enhanced efficacy in the regulation of NMDA receptor activity, and the use of such compounds for preventing / treating depression, anxiety, tension, learning and cognitive deficits, neuropathic pain and other diseases. Background technique [0002] At present, the incidence and harm of depression are increasing day by day, but the treatment drugs for depression have not fully met the clinical needs. The marketed antidepressants are mainly selective serotonin (5-HT) reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), which regulate 5-HT Antidepressants with the core mechanism have many defects, including slow onset of action, more adverse reactions, and more non-responsive p...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K5/103A61K38/07A61P25/24A61P25/22A61P9/10A61P25/28A61P25/00A61P25/18A61P25/14
CPCC07K5/1008C07K5/101A61P25/24A61P25/22A61P9/10A61P25/28A61P25/00A61P25/18A61P25/14A61K38/00
Inventor 顾为
Owner BEIJING GREATWAY PHARMA TECH CO LTD